7061-92-9

Basic information

• Product Name: 1,4-bis(2,4-dinitrophenyl)piperazine
• Synonyms: 1,4-Bis(2,4-dinitrophenyl)piperazine
• CAS NO: 7061-92-9
• Molecular Formula: C₁₆H₁₄N₆O₈
• Molecular Weight: 418.3178
• Mol File: 7061-92-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 661.3°C at 760 mmHg
• Flash Point: 353.8°C
• Density: 1.582g/cm³
• Vapor Pressure: 2.32E-17mmHg at 25°C
• Refractive Index: 1.686
• CAS DataBase Reference: 1,4-bis(2,4-dinitrophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-bis(2,4-dinitrophenyl)piperazine(7061-92-9)
• EPA Substance Registry System: 1,4-bis(2,4-dinitrophenyl)piperazine(7061-92-9)

Safety Data

• Hazardous Substances Data: 7061-92-9(Hazardous Substances Data)

Usage

Synonyms

Bis(p-phenyl-2,4-dinitrophenyl) piperazine (BDNP)

Chemical structure

Piperazine derivative with two nitrophenyl groups attached to the piperazine ring

Industry use

Pharmaceutical and chemical industry

Application

Intermediate in the synthesis of biologically active compounds

Reagent use

Detection of primary and secondary amines

Additional uses

Synthesis of dyes, pharmaceuticals, and other organic compounds

Research

Potential use as an anti-cancer agent and for its cytotoxic properties

Safety

Toxic compound, requires careful handling to avoid health risks

Upstream product

• 110-85-0 piperazine 
• 70-34-8 2,4-Dinitrofluorobenzene 
• 97-00-7 1-chloro-2,4-dinitro-benzene 

Relevant articles and documents

Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer

Prodrugs for targeted tumor therapies have been extensively studied in recent years due to not only maximising therapeutic effects on tumor cells but also reducing or eliminating serious side effects on healthy cells. This strategy uses prodrugs which are safe for normal cells and form toxic metabolites (drugs) after selective reduction by enzymes in tumor tissues. In this study, prodrug candidates (1-36) containing nitro were designed, synthesized and characterized within the scope of chemical experiments. Drug-likeness properties of prodrug candidates were analyzed using DS 2018 to investigate undesired toxicity effects. In vitro cytotoxic effects of prodrug canditates were performed with MTT assay for human hepatoma cells (Hep3B) and prostate cancer cells (PC3) and human umbilical vein endothelial cells (HUVEC) as healthy control. Non-toxic compounds (3, 5, 7, 10, 12, 15, 17, 19 and 21–23), and also compounds (1, 2, 5, 6, 9, 11, 14, 16, 20 and 24) which had low toxic effects, were selected to examine their suitability as prodrug canditates. The reduction profiles and kinetic studies of prodrug/Ssap-NtrB combinations were performed with biochemical analyses. Then, selected prodrug/Ssap-NtrB combinations were applied to prostate cancer cells to determine toxicity. The results of theoretical, in vitro cytotoxic and biochemical studies suggest 14/Ssap-NtrB, 22/Ssap-NtrB and 24/Ssap-NtrB may be potential prodrug/enzyme combinations for nitroreductase (Ntr)-based prostate cancer therapy.